Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163213 · ClinicalTrials.gov registry record · NA
Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D
A NA study of Diarrhea-Predominant Irritable Bowel Syndrome, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02163213: Completed NA study of Diarrhea-Predominant Irritable Bowel Syndrome, sponsored by Mayo Clinic.
NCT02163213 is a NA study of Diarrhea-Predominant Irritable Bowel Syndrome that has completed, run by Mayo Clinic. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02163213, a NA study of Diarrhea-Predominant Irritable Bowel Syndrome, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines in subjects with IBS-D.
Primary Outcome
The primary endpoints for the study are change from baseline in mucosal expression of tight junction proteins (ZO-1, occludin, claudin)
Conditions Studied
Interventions
- OTHER Serum-derived bovine immunoglobulin protein isolate (SBI)
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-11-02 |
| Phase | NA |
What the finished NCT02163213 record still lists
NCT02163213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diarrhea-Predominant Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Serum-derived bovine immunoglobulin protein isolate (SBI) is the first listed.
NCT02163213 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02163213 about?
NCT02163213 is a clinical study titled "Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D". To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines in subjects...
What is the current status of trial NCT02163213?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2014-06. Estimated completion is 2016-11-02.
What conditions does trial NCT02163213 study?
This clinical trial studies the following conditions: Diarrhea-Predominant Irritable Bowel Syndrome.
What interventions are being tested in trial NCT02163213?
The interventions under investigation include: Serum-derived bovine immunoglobulin protein isolate (SBI) (OTHER).
Who is sponsoring clinical trial NCT02163213?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02163213 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea-Predominant Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02163213's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia